drugset / Trial / NCT06333691

Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin

NCT06333691

Completed 180 enrolled Minia University
RandomizedParallel-groupSingle-blindPrevention

Summary

Ovarian hyperstimulation syndrome is a potentially fatal iatrogenic condition. This syndrome is characterized by a sudden increase of the vascular permeability which results in the development of a massive extravascular exudate in the peritoneal cavity, pleural, pericardium causing ascites, pleural and pericardial effusion. Severe forms are also accompanied by electrolyte disturbances and cardiopulmonary, hepatic, renal, and hemoconcentration associated with increased thromboembolic risk. This syndrome is avoidable by the judicious use of gonadotropins and careful monitoring of stimulation regimens.

Timeline

Start
2022-10-01
Primary completion
2024-02-01
Completion
2024-02-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cabergoline Small molecule 0.5 mg Oral
Comparator Diosmin Small molecule 500 mg Oral
Comparator calcium gluconate Small molecule 10 ml Intravenous